FPH (Fisher & Paykel Healthcare Corporation Ltd) vs S&P/ASX 300 Comparison

FPH

S&P/ASX 300

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap Between FPH and AXKO

Show

FPH

S&P/ASX 300

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

S&P/ASX 300

FPH

LEG

PMT

GNL

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Fisher & Paykel Healthcare Corporation Ltd
Glance View

Economic Moat

Narrow

Market Cap

19.7B AUD

Industry

Health Care

Nestled in the heart of New Zealand, Fisher & Paykel Healthcare Corporation Ltd. has emerged as a formidable player in the global healthcare market, largely due to its innovative spirit and relentless focus on respiratory care solutions. Originally part of Fisher & Paykel Industries, the healthcare division carved its own path in 2001, quickly becoming synonymous with high-quality medical devices. The company’s journey can be compared to a constant rhythm of innovation, particularly in areas that address obstructive sleep apnea, acute respiratory distress, and surgical humidification. Its revenue streams are primarily bolstered by a diverse array of products, including sleep apnea masks, humidifier systems for intensive care units, and related respiratory accessories. These offerings are not just technological marvels but are designed to improve patient outcomes and their quality of life, which resonates well with healthcare providers worldwide. Over the years, Fisher & Paykel Healthcare has strategically expanded its operations beyond its Kiwi roots, anchoring its presence in over 120 countries. This global footprint, coupled with a robust pipeline of patented products, enables sustained revenue growth and stability. The company’s financial health is driven by a business model that emphasizes research and development, ensuring that it remains at the forefront of medical innovation. By fostering close relationships with healthcare professionals and institutions, Fisher & Paykel not only gains invaluable insights to refine its products but also cultivates a loyal customer base. This enduring approach cements its position not only as a leader in the healthcare sector but also as a trusted partner in the critical mission to enhance patient care worldwide.

View FPH Analysis

FPH Intrinsic Value

Show

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

FPH

vs

S
S&P/ASX 300

Stocks Performance
FPH vs S&P/ASX 300

Performance Gap
FPH vs S&P/ASX 300

Performance By Year
FPH vs S&P/ASX 300

Competitors Performance
Fisher & Paykel Healthcare Corporation Ltd vs Peers

Fisher & Paykel Healthcare Corporation Ltd
Glance View

Company

Help

Tools

Stocks

FPH vs S S&P/ASX 300

Stocks Performance FPH vs S&P/ASX 300

Performance Gap FPH vs S&P/ASX 300

Performance By Year FPH vs S&P/ASX 300

Competitors Performance Fisher & Paykel Healthcare Corporation Ltd vs Peers

Fisher & Paykel Healthcare Corporation Ltd Glance View

Company

Help

Tools

Stocks

FPH

vs

S
S&P/ASX 300

Stocks Performance
FPH vs S&P/ASX 300

Performance Gap
FPH vs S&P/ASX 300

Performance By Year
FPH vs S&P/ASX 300

Competitors Performance
Fisher & Paykel Healthcare Corporation Ltd vs Peers

Fisher & Paykel Healthcare Corporation Ltd
Glance View